Idera Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Idera Pharmaceuticals, Inc.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors
All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.
Protagonist/J&J Explore Autoimmune FRONTIER With Positive Psoriasis Results
While full data are not yet available, JNJ-2113 would be the first oral drug against IL-23R, setting up for potential competition against oral TYK2 and IL-17-targeting drugs.
Worldwide Regulators Warm Up To Medical Marijuana
Both the US and EU are gradually warming up to medical marijuana, but clunky and inadequate regulation threatens to curtail the growth of a burgeoning industry.
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
- Hybridon Inc.
- Idera Pharmaceuticals, Inc.
- Idera Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.